Literature DB >> 9454660

Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment.

J Brugghe1, J P Baak, E Wiltshaw, M Brinkhuis, G A Meijer, C Fisher.   

Abstract

To identify FIGO I ovarian cancer patients at high risk, prognostic values of quantitative pathological features (volume percentage of epithelium, mitotic activity index, mean (MNA) and standard deviation of nuclear profile area, and volume-weighted mean nuclear volume (MNV) have been investigated in comparison with clinical features, histological grade, and type in 102 adequately staged patients with FIGO Ia, Ib, and Ic ovarian cancer of the common epithelial types. None of these patients received any postoperative treatment. Overall survival of patients alive and well was 78%, and 90% were alive. Of the clinical features, FIGO substage was the strongest prognosticator (Mantel-Cox = 7.2, p = 0.03, hazard ratio (HR) = 4.6). Histologic grade had significant prognostic value as well (Mantel-Cox = 9.7, p = 0.008, HR = 5.9), but histologic type did not. MNA and MNV were the strongest single prognostic factors for overall survival (Mantel-Cox = 12.3 for both; p = 0.0004 and 0. 0005). If MNA </= 55.6 micron2, none of the patients (n = 52) died; if MNA >55.6 micron2, 6-year overall survival was 69%. For MNV </=460 micron2, none of the patients (n = 53) died; if MNV >460 micron2, 6-year overall survival was 70%. A multivariate combination of MNA and FIGO (early cancer of the ovary prognostic score, ECOPS) had the strongest prognostic value (p < 0.0001 and Mantel-Cox value = 22.8, HR = 29.2). If ECOPS </= 5.4 (n = 66), 6-year overall survival was 97%; if ECOPS >5.4 (n = 36), 6-year overall survival was 54%. The results from this and earlier studies emphasize the strong prognostic value of easy to assess and highly reproducible morphometric nuclear features in ovarian tumors and offer a useful instrument for the definition of patient groups for future clinical trials. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 9454660     DOI: 10.1006/gyno.1997.4884

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Anette Kjaerbye-Thygesen; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

Review 2.  Early ovarian cancer.

Authors:  G Coukos; S C Rubin
Journal:  Curr Treat Options Oncol       Date:  2000-06

3.  Morphological and molecular basis of ovarian serous carcinoma.

Authors:  Daniel G Rosen; Zhihong Zhang; Weiwei Shan; Jinsong Liu
Journal:  J Biomed Res       Date:  2010-07

4.  Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.

Authors:  Aristotle Bamias; Christos Papadimitriou; Eleni Efstathiou; Alexandros Rodolakis; Georgios Vlahos; Zannis Voulgaris; Georgios Bozas; Georgios Fountzilas; Gerassimos Aravantinos; Evagelia Razis; Dimitra Gika; Meletios A Dimopoulos
Journal:  BMC Cancer       Date:  2006-09-25       Impact factor: 4.430

5.  Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens.

Authors:  Chien An Chen; Chun Ju Chiang; Yun Yuan Chen; San Lin You; Shu Feng Hsieh; Chao Hsiun Tang; Wen Fang Cheng
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

6.  Prognostic factors in early-stage ovarian cancer.

Authors:  Germana Tognon; Mario Carnazza; Monica Ragnoli; Stefano Calza; Federico Ferrari; Angela Gambino; Valentina Zizioli; Sara Notaro; Benedetta Sostegni; Enrico Sartori
Journal:  Ecancermedicalscience       Date:  2013-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.